


NASDAQ: POCI

Corporate Presentation
May 2023



Forward-Looking Statements

This presentation contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that the Company files from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

Non-GAAP Financial Measures

In addition to financial results reported in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company has provided the following non-GAAP financial measures in this release and the accompanying tables: adjusted EBITDA. Precision Optics uses this non-GAAP financial measures internally to facilitate period-to-period comparisons and analysis of its operating performance and liquidity, and believes they are useful to investors as a supplement to GAAP measures in analyzing, trending and benchmarking the performance and value of our business. However, these measures are not intended to be a substitute for those reported in accordance with GAAP. These measures may be different from non-GAAP financial measures used by other companies, even when similar terms are used to identify such measures.

In order to calculate these non-GAAP financial measures, the Company makes targeted adjustments to certain GAAP financial line items found on its Consolidated Statement of Operations, backing out non-recurring or unique items or items that the Company believe otherwise distort the underlying results and trends of the ongoing business. We have excluded the following items from one or more of our non-GAAP financial measures for the periods presented:

Selling, general and administrative expenses; operating expenses. The Company excludes a portion of SG&A expense and operating expenses related to transaction expenses related to acquisitions and financings. Acquisition-related expenses include transaction fees, due diligence costs and other direct costs associated with our acquisitions. These amounts are unrelated to our core performance during any particular period and are impacted by the timing of the acquisition. The Company excludes acquisition-related expenses from the Company's SG&A expense and total operating expenses to provide investors a method to compare our operating results to prior periods and to peer companies, as such amounts can vary significantly based on the frequency of acquisitions and the magnitude of acquisition expenses.

Bad debt expense; operating expenses. The Company excludes a portion of SG&A expense and operating expenses related to bad debt expense. These amounts are unrelated to our core performance during any particular period. The Company believes it is useful to exclude these amounts in order to better understand our business performance and allow investors to compare the Company's results with peer companies.

Adjusted EBITDA is a non-GAAP financial measure that we define as GAAP net income (loss), adjusted to exclude non-recurring transaction costs, bad debt expense, depreciation and amortization, non-cash stock-based compensation, interest expense, and provision (benefit) for income taxes. We believe that the use of adjusted EBITDA is useful to investors and other users of the Company's financial statements in evaluating our operating performance because it provides them with an additional tool to compare business performance across companies and across periods. The Company uses adjusted EBITDA in conjunction with traditional GAAP operating performance measures as part of our overall assessment of our performance, for planning purposes, including the preparation of our annual operating budget, to evaluate the effectiveness of our business strategies and to communicate with our board of directors concerning our financial performance. Management does not place undue reliance on adjusted EBITDA as its only measure of operating performance. Adjusted EBITDA should not be considered as a substitute for other measures of financial performance reported in accordance with GAAP.

Enabling Next Generation Technologies

Precision Optics **ENABLES** leading medical devices companies around the world to meet the increasing demands of the surgical community who are requiring more enhanced and **SMALLER IMAGING SYSTEMS FOR MINIMALLY INVASIVE SURGERY** as well as the rapid proliferation of **3D ENDOSCOPES FOR SURGICAL ROBOTIC SYSTEMS.**




Company Overview

- ▶ **Precision Optics (Nasdaq: POCI) has been a leading developer and manufacturer of advanced optical instruments for more than 35 years addressing the medical device and defense market. Recent focus has been on:**
 - ▶ Micro Optics
 - ▶ 3D Endoscopes
 - ▶ Digital Imaging
- ▶ **Business model transition driving rapid growth**
 - ▶ Work closely with key medical device and defense companies at the very early design stage of projects, lending the Company's expertise in proprietary micro-optics and 3D imaging technologies
 - ▶ Robust pipeline supporting future commercial production opportunities
- ▶ **Strategic initiatives to drive future growth**
 - ▶ Augment our own skills and programs via external partnership or acquisitions
 - ▶ Ross Optical acquisition in 2019 broadened capabilities and accelerates efforts to gain economies of scale
 - ▶ Acquisition of Lighthouse Imaging in October 2021 to broaden optical electronics capabilities
 - ▶ Grow sales capabilities and capacity
 - ▶ Invest in technical resources and develop Company owned intellectual property
 - ▶ Invest in and update production capabilities to expand market opportunity and improve efficiencies




40 Year Old Growth Story



Revenue Ramp


FY End June



A robotic arm, primarily white with blue accents, is shown in a close-up, angled view. It holds a precision tool that emits a fine, bright white beam of light. The background is a deep blue with a subtle pattern of out-of-focus circular lights. A dark blue rectangular box with a thin yellow horizontal line at its base is positioned on the left side of the image.

**LEADER IN MICRO,
3D OPTICS AND
DIGITAL IMAGING**

MicroPrecision Optics




- ▶ Millimeter sized and smaller cameras with low manufacturing costs
- ▶ Small size can provide visualization for new procedures in new parts of the body and for existing procedures that are currently performed blind or with sub-optimal imaging. Facilitates the development of new surgical procedures that are currently impractical.
- ▶ Patented and patent pending approaches to fabricating opto-mechanical and opto-electronic systems
- ▶ Best-in-class technical organization with 25+ years of experience to design and fabricate components and systems at industry's smallest sizes
- ▶ Commercialized and development applications in medical device and defense industry
- ▶ Market driven by surgical community that is demanding smaller and more enhanced imaging systems for minimally invasive surgery
 - ▶ Brain, eye, ear, urology, cardiology/angiography, spine

3D Endoscopes and Robotic Surgery Systems



- ▶ One of only a handful of companies in the world to design and provide 3D endoscopes
- ▶ Precision Optics 3D endoscopes provide next generation optical imaging for minimally invasive surgical procedures, many employing medical robotic technology, by using the brain's natural ability to perceive depth, which is the third dimension, by viewing one's environment through two eyes.
- ▶ Best-in-class technical organization with 20+ years of experience with 3D technology, that can design and fabricate 3D endoscopes and imaging systems for most demanding next-generation robotic systems
- ▶ Competition amongst medical device companies is increasing with multiple companies now pursuing less expensive, procedure specific robotic systems.

Digital Imaging Electronics and Systems



- ▶ With the growing movement towards CMOS sensors in next generation devices, imaging system electronics are becoming increasingly critical to creating optimal solutions to our customer's requirements.
- ▶ Our product development team has extensive experience developing visualization systems that are used in a variety of clinical applications.
- ▶ Technical capability and experience in design and manufacture of electronic systems required to support CMOS-based imaging and LED illumination.
- ▶ Broad technical resources to support integrated system development including Optical, Mechanical, Electrical, Systems and Process Engineering .
- ▶ Full system design capability including handheld devices (single-use and reusable) and console capital equipment.

Traditional Applications



- ▶ Complex endocoupler production for more than 30 years
- ▶ Specialized endoscope for top tier medical company for more than 20 years
- ▶ Custom spinal surgery product utilizing Precision Optics illumination technology for top tier medical company for more than 10 years
- ▶ Multiple Microprecision™ optical components and assemblies for use in medical devices

Ross Optical Industries Acquisition & Integration

- ▶ Extends product offering to include a wider range of lens and optical system sizes
- ▶ Expands presence in the U.S. defense sector where Ross has a significant number of customers that do not overlap with POC
- ▶ Allows the combined company to leverage Precision Optics' technical proficiency in offering end-to-end solutions, from design through production, to the expansive Ross Optical customer base, increasing its value-add capabilities.
- ▶ Ross Optical had revenues of \$4.4 M and net income of \$480,000 for the 12-mo. ended June 30, 2019.
- ▶ The total purchase price of up to \$2 million, comprised of \$1.5 million in cash at closing and additional payments up to \$500,000 subject to a three-year earnout provision.
 - ▶ Precision Optics completed an equity capital raise of \$950,000 at a per share price of \$1.25 concurrent with the closing of the acquisition.
 - ▶ As part of the transaction, Precision Optics is acquiring slightly over \$1 million of net working capital.
- ▶ Successful integration; first "joint" customer contract awarded for \$1.5 million over 6 months


Incorporated in 1989, Ross Optical has evolved from an optical components supplier into an expanded solutions provider. They have an extensive portfolio of optical fabrication and quality assurance equipment, technology, and technical solutions that supply a number of industries, including the defense, medical and industrial markets. Focused on high quality and difficult-to-find optical components, Ross Optical provides custom solutions as well as a wide range of standard lens sizes in an extensive catalog offering, through a robust worldwide sourcing network that allows them to provide cost-efficient optical components and assemblies.

Lighthouse Imaging Acquisition


- ▶ Acquisition combines two of the industry's leaders in medical optics and digital imaging, leveraging Precision Optics next generation capabilities in micro-optics and optical systems with Lighthouse Imaging's advanced capabilities and strong reputation in leading-edge optical imaging electronics.
- ▶ Precision Optics and Lighthouse Imaging believe that up to four new projects may transition from engineering to production in the coming twelve months, providing opportunities for significant growth. Additionally, Lighthouse Imaging has a robust and expanding project pipeline for which they are compensated for their services, similar to Precision Optics.
- ▶ Lighthouse had revenues of approximately \$4.5 million and EBITDA of \$232,000 for the 12-mo. ended June 30, 2021. Currently, Lighthouse Imaging generates approximately 66% of its revenue from engineering services, with the remainder attributable to production agreements. Production revenue is expected to increase as projects advanced to commercialization in the coming year.
- ▶ The total purchase price of \$2.85 million in cash, along with 833,333 shares (split adjusted) of PEYE at closing and additional payments subject to certain earnout provisions over the next 2 years.
 - ▶ Precision Optics completed an equity capital raise of \$1.5 million at a per share price of \$4.80 (split adjusted) concurrent with the closing of the acquisition.
 - ▶ Closed on a \$2.6 million 7-year term loan with variable rate of Prime +1.5% (4.75% minimum)



Founded in the late 1980s, Lighthouse Imaging has leveraged its unique engineering capabilities to assist large-established companies, as well as well-funded startup companies, develop next generation applications in the medical device industry.



Medical Device Imaging



Optics

Performance
Size
Fabrication
Assembly
Alignment



Image Sensor

Performance
Size
Interconnect
Mounting
Signal integrity



Illumination

Luminance
Distribution
Power & Thermal
Packaging
Assembly




Video Processing

Quality
Flexibility
Latency
Tuning
Features



Packaging

Sterilization
Biocomp.
Size
Durability
Appearance




System

Product Cost
Quality
Compliance
Project Mgmt.
DFx



Vertically Integrated Capabilities

Broad Optical Capabilities All Under One Roof



- ▶ **Vertically integrated capabilities** enable Precision Optics to uniquely apply customization requirements and demands of its customers on base technological capabilities that others in the industry simply are unable to accomplish
- ▶ Allows Company to accelerate product development and regulatory clearance for its customers
- ▶ Aspects to technology that provide the greatest benefit if used in production in a certain way which is only accomplished by having integrated design and production teams

- ▶ **Acquisition of Ross Optical** extends product offering to include a wider range of lens and optical system sizes
- ▶ Extensive portfolio of optical fabrication and quality assurance equipment, technology, and technical solutions that supply a number of industries, including the defense, medical and industrial markets.
- ▶ Focused on high quality and difficult-to-find optical components, Ross Optical provides custom solutions as well as a wide range of standard lens sizes in an extensive catalog offering, through a robust worldwide sourcing network that allows them to provide cost-efficient optical components and assemblies.

- ▶ **Acquisition of Lighthouse Imaging** combines two of the industry's leaders in medical optics and digital imaging, leveraging Precision Optics next generation capabilities in micro-optics with Lighthouse Imaging's advanced capabilities and strong reputation in leading-edge optical electronics.
- ▶ Significant opportunities to leverage each other's respective strengths surrounding micro optics, 3D imaging, manufacturing, and optical imaging electronics to accelerate product development timelines and offer enhanced capabilities to its customers.


Expanding Product Pipeline

Product	Feasibility Study	Prototype Design	Prototype Fabrication	Pilot	Production	Industry	Subsegment	Customer	
Multiple Mature “Legacy” Products	<div></div>					Medical Device	Multiple	Multiple	
Cardiovascular Endoscope	<div></div>					Medical Device	Cardiac	CardioFocus	
Otoscopy Device #1	<div></div>					Medical Device	Otoscopy	Large Medical Device	
Micro Optics Components	<div></div>					Defense/Aerospace	Confidential	Tier One Defense/Aerospace	
Otoscopy Device #2*	<div></div>					Medical Device	Otoscopy	Well-funded Startup	
Colonoscope	<div></div>					Medical Device	Colonoscopy	Well-funded Startup	
Optics Components	<div></div>					Defense/Aerospace	Confidential	Top Tier Defense/Aerospace	
Arthroscope #1*	<div></div>					Medical Device	Arthroscopy	Mid-Tier Medical Device	
Ophthalmic Scanning Device*	<div></div>					Medical Device	Ophthalmology	Well-funded Startup	
Arthroscope #2*	<div></div>					Medical Device	Arthroscopy	Well-funded Startup	
Micro Endoscope	<div></div>					Medical Device	Ophthalmology	Mid-Tier Medical Device	
Laparoscope*	<div></div>					Medical Device	Robotic Laparoscopy	Well-funded Startup	
Cystoscope #1	<div></div>					Medical Device	Robotic Surgery	Mid-Tier Medical Device	
Advanced Surgical Device	<div></div>					Medical Device	Abdominal Surgery	Well-funded Startup	
ENT Scope*	<div></div>					Medical Device	Ear, Nose and Throat	Well-funded Startup	
Otoscopy Device #3	<div></div>					Medical Device	Otoscopy	Well-funded Startup	
Ureteroscope	<div></div>					Medical Device	Urology	Mid-Tier Medical Device	
Non-Contact Inspection Device	<div></div>					Defense/Aerospace	Aviation	Well-funded Startup	
Cystoscope #2*	<div></div>					Medical Device	Cystoscopy	Well-funded Startup	
3D Laparoscope*	<div></div>					Medical Device	Robotic Laparoscopy	Well-funded Startup	
Multiple projects in quotation / discussion stage									


* Acquired through recent acquisition of Lighthouse Imagine

Growth of Commercialized Products

- ▶ Reaching “critical mass” for production supports broader resources (and greater efficiency) which helps accelerate future growth
- ▶ Once medical device products reach commercialization they tend to continue for long time periods: Two Precision Optics legacy products have 10 and 20 year lifetimes (and counting)
- ▶ Multiple products have reached commercialization level production since middle of 2018




Expanding Markets for Micro Optics, 3D & Digital Imaging Systems



Go Forward Strategy Summary

- ▶ Drive growth and efficiencies in currently commercialized products
- ▶ Advance pipeline projects to commercialization
- ▶ Maintain competitive advantages in micro optics, 3D imaging and digital imaging in medical devices, while expanding applications of existing technologies to defense market
- ▶ Disciplined investment strategy in sales and marketing, as well as engineering capabilities
- ▶ Recognize operational benefits from Ross Optical and Lighthouse Imaging acquisitions
- ▶ Look for strategic acquisitions to broaden the Company's existing capabilities or by extending vertical integration of existing opto-mechanical medical and defense based product focus


FINANCIALS



Revenue


Annual

FY ends June



Year to Date


FY ends June



Gross Margins


Annual

FY ends June



Year to Date


FY ends June



Adjusted EBITDA


Annual

FY ends June



Year to Date

FY ends June



Income Statement

FY End June

	FY 2018	FY 2019	FY 2020	Q1	Q2	Q3	Q4	FY 2021	Q1	Q2	Q3	Q4	FY 2022	Q1	Q2	Q3
Revenues	4,038,048	6,804,169	9,923,356	2,757,901	2,785,451	2,458,289	2,673,266	10,674,907	2,336,344	3,897,041	4,651,352	4,793,511	15,678,248	5,085,301	5,886,961	5,048,065
Cost of Goods Sold	2,556,130	4,681,691	6,560,779	1,782,723	1,931,012	1,640,265	1,887,323	7,241,323	1,697,312	277,459	2,923,142	3,352,148	10,750,061	3,445,860	3,287,489	3,311,967
Gross Profit	1,481,918	2,122,478	3,362,576	975,178	854,439	818,024	785,943	3,433,584	314,122	1,119,582	1,728,210	1,441,363	4,928,187	1,639,441	2,599,472	1,736,098
Operating Expenses	1,830,537	2,735,021	4,785,559	973,578	1,067,165	1,074,040	1,224,375	4,339,158	961,970	1,579,932	1,789,329	1,861,833	6,442,078	1,741,243	2,028,407	2,229,366
Operating Income (Loss)	(348,619)	(612,543)	(1,422,983)	1,600	(212,726)	(256,016)	(438,432)	(905,574)	(571,952)	(460,350)	(61,119)	(420,470)	(1,513,891)	(101,802)	571,065	(493,268)
Other - Interest Expense	(1,859)	(1,416)	(1,001)	(807)	(730)	(666)	(3,100)	(5,302)	(28,277)	(29,274)	(52,778)	(55,148)	(159,538)	(56,922)	(62,397)	(48,124)
Other Income	-	-	-	-	-	808,962	-	808,962	-	-	-	745,863	745,963	-	-	142,960
Income Tax	(912)	(912)	(2,165)	-	-	-	(912)	(912)	-	-	-	(952)	(952)	-	-	-
Net Income (Loss)	(351,390)	(614,871)	(1,426,149)	793	(213,456)	552,280	(442,443)	(102,826)	(576,801)	(489,624)	(113,897)	269,293	(928,418)	(158,724)	508,668	(398,432)
Stock Comp & Services Expense	52,341	473,326	547,345	71,146	157,079	86,027	419,678	733,930	160,071	350,452	231,115	173,856	915,494	74,990	244,786	450,014
Business Acquisition Expenses	-	128,111	-	-	-	-	-	-	172,174	(10,049)	-	-	162,125	-	-	-
Other Income	-	-	-	-	-	(808,962)	-	(808,962)	-	-	-	(742,052)	(742,052)	-	-	-
Depreciation & Amortization	27,216	38,554	112,218	35,086	35,642	33,779	42,419	146,926	42,291	47,391	48,197	52,189	190,068	52,083	52,667	52,710
Interest Expense	-	1,416	1,001	807	730	666	3,100	5,302	4,849	29,274	52,778	55,148	159,538	56,922	62,397	48,124
Income Taxes	912	912	2,165	-	-	-	912	912	-	-	-	952	952	-	-	-
Add Bad Debt Expense	227,500	9,803	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adjusted EBITDA	(43,421)	37,251	(763,419)	107,832	(20,005)	(136,210)	23,665	(24,718)	(197,416)	(72,555)	218,193	(190,614)	(242,293)	25,271	868,518	9,456

Balance Sheet Highlights

	6/30/2020	6/30/2021	6/30/2022	3/31/2023
Cash and cash equivalents	\$1,134,697	\$861,650	\$605,749	\$612,095
Accounts receivable, net	\$1,481,437	\$1,878,755	\$2,663,872	\$4,389,907
Inventory	\$2,197,244	\$1,885,395	\$3,079,938	\$2,959,732
Total assets	\$6,351,531	\$6,261,300	\$16,704,020	\$18,186,643
Current Liabilities	\$3,149,380	\$2,511,110	\$4,586,641	\$6,494,712
Acquisition earn out liability (incl. current portion)	\$500,000	\$333,333	\$872,559	\$571,838
Debt (incl. current portion)	\$0	\$0	\$2,328,855	\$2,053,071
Total shareholder's equity	\$2,771,761	\$3,431,127	\$8,971,495	\$9,697,897
Shares Outstanding*	4,397,263	4,427,492	5,638,363	5,640,995

*Reflects 1-for-3 split enacted on November 2, 2022